Animal diseases

BioAge Initiates Phase 2 Trial of BGE-175 to Treat COVID-19 by Reversing Immune Aging, a Key Cause of Morbidity and Mortality in Older Patients

Retrieved on: 
Monday, March 22, 2021
Health, Consumer, Infectious diseases, Seniors, Clinical trials, Pharmaceutical, Biotechnology, Sarbecovirus, Respiratory diseases, Zoonoses, Animal diseases, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, the Phase 2 trial, BGE-175, the BioAge Platform, BioAge

By reversing age-related dysregulation of critical immune mechanisms, BGE-175 could allow older patients to more effectively fight off COVID-19.

Key Points: 
  • By reversing age-related dysregulation of critical immune mechanisms, BGE-175 could allow older patients to more effectively fight off COVID-19.
  • Our strongly encouraging preclinical data show that BGE-175 almost completely protects older mice against lethality from infection with SARS-CoV-2, the virus that causes COVID-19.
  • In addition, BGE-175 dramatically decreases viral load in lung tissue, which is correlated with both disease severity and transmission of the virus.
  • DP1 signaling becomes dysregulated with aging and adversely affects the immune response of older animals to SARS-CoV-2 and other viral challenges.

Study Examining 630,000 Patients Unveils COVID-19 Outcome Disparities Across Racial/Ethnic Lines

Retrieved on: 
Thursday, March 18, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Severe acute respiratory syndrome, Animal diseases, Coronavirus disease, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus, Variant of concern

The team looked at sociodemographic and clinical characteristics of patients who were part of the Providence healthcare system in Washington, Oregon and California.

Key Points: 
  • The team looked at sociodemographic and clinical characteristics of patients who were part of the Providence healthcare system in Washington, Oregon and California.
  • These patients had SARS-CoV-2 tests administered between March 1 and December 31 of 2020.
  • "All minority races/ethnicities faced increased odds of testing positive for SARS-CoV-2 and being hospitalized with COVID-19," said Chengzhen Dai, lead author of the study.
  • "Hispanic patients also exhibited increased morbidity, and Hispanic race/ethnicity was associated with increased odds of in-hospital mortality."

New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology’s PBI-06150 Against SARS-CoV-2

Retrieved on: 
Wednesday, March 17, 2021
Biotechnology, FDA, Health, Other Health, Pharmaceutical, Oncology, Other Science, Mental health, Research, Managed care, Infectious diseases, General Health, Hospitals, Science, Sarbecovirus, Zoonoses, Health sciences, Animal diseases, Biomedicine & Pharmacotherapy, Coronavirus disease, Pharmacotherapy, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, Coronavirus

View the full release here: https://www.businesswire.com/news/home/20210317005066/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210317005066/en/
    The Journal of Biomedicine & Pharmacotherapy is an open access, peer-reviewed medical journal covering medical applications of pharmacology.
  • Moreover, it is possible that vaccines may require continuous development due to the ongoing mutation of coronavirus into different variants .
  • The article is a collaborative effort which covers the results of two separate studies of the impact of oleandrin and PBI-06150 on SARS-CoV-2.
  • Preliminary discussions with the FDA have resulted in the request for additional studies to explore both efficacy and safety.

GenScript and G42 Healthcare announce collaboration to provide innovative solutions to fight against COVID-19

Retrieved on: 
Wednesday, March 17, 2021
Bat virome, G42, Severe acute respiratory syndrome, Infectious diseases, Medical specialties, Animal diseases

The collaboration includes the distribution of the GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit across 24 geographies in the MENA region toassessvaccine effectiveness.

Key Points: 
  • The collaboration includes the distribution of the GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit across 24 geographies in the MENA region toassessvaccine effectiveness.
  • "We are glad to be working with G42 Healthcare and contribute to the development of innovative solutions to help the people of the UAE and beyond.
  • Mr. Ashish Koshy, CEO, G42 Healthcare, said, "Our mission is to provide the definitive, comprehensive and most technologically advanced healthcare solutions in the GCC region.
  • G42 Healthcare, a leading health technology company, is committed to developing a world-class, sustainable healthcare sector in the UAE and beyond.

Colorado State University, Flint Animal Cancer Center Applies Sensus Healthcare’s SRT Non-Surgical Treatment to Animal Care

Retrieved on: 
Tuesday, March 16, 2021
Animal diseases, Dogs, Mastocytoma, SRT, Bulldog, Colorado State University, Radiation therapy, Animal health

SRT-100 systems utilize Sensus Healthcares proprietary low-energy x-ray technology known as superficial radiation therapy (SRT) that enables radiation therapy to target harder-to-reach lesions, such as those often found in animal patients.

Key Points: 
  • SRT-100 systems utilize Sensus Healthcares proprietary low-energy x-ray technology known as superficial radiation therapy (SRT) that enables radiation therapy to target harder-to-reach lesions, such as those often found in animal patients.
  • The canine, an American bulldog, named Daisy, was treated at Flint Animal Cancer Center at the Colorado State University (CSU) James L. Voss Veterinary Teaching Hospital.
  • The agreement with the school calls for the development of protocols for SRT use and the publishing of clinical data.
  • Daisy was diagnosed with two small mast cell tumors, one on her muzzle and the other on her lower eyelid.

Eurofins Adds Virus Variant Detection to its SARS-CoV-2 Monitoring Solution for Wastewater, Surface, Air and Worn Masks

Retrieved on: 
Friday, March 12, 2021
Medical Supplies, Health, Infectious diseases, Other Health, Pharmaceutical, Biotechnology, Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Severe acute respiratory syndrome, Wastewater surveillance

Eurofins (Paris:ERF) adds virus variant monitoring capabilities to its commercially available SARS-CoV-2 test portfolio.

Key Points: 
  • Eurofins (Paris:ERF) adds virus variant monitoring capabilities to its commercially available SARS-CoV-2 test portfolio.
  • a city, factories, education institutions, government and public service sites, nursing homes), before the virus spreads too broadly.
  • The monitoring of wastewater, environmental surface, air and worn mask testing can give an early indication of the presence of SARS-CoV-2 and can also detect virus variants.
  • In the US, in addition to qualitative surface and worn mask testing the quantification of SARS-CoV-2 in wastewater and air provides crucial information for monitoring viral spread.

UVDI V-MAX™ UV-C Technology Proven to Eliminate 99.99% of Airborne SARS-CoV-2 in Moving Airstream HVAC Testing

Retrieved on: 
Thursday, March 11, 2021
Building Systems, Commercial Building & Real Estate, Construction & Property, Manufacturing, Technology, General Health, Infectious diseases, Environment, Other Technology, Other Manufacturing, Science, Other Science, Health, Architecture, Research, Sarbecovirus, Zoonoses, Animal diseases, Medical specialties, Ultraviolet radiation, Animal virology, Bat virome, ASHRAE, Coronavirus disease, Ultraviolet, Coronavirus, Coronavir

UltraViolet Devices, Inc. (UVDI) announced its V-MAX UV-C air disinfection technology has achieved 99.99% inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in a single-pass in moving airstream HVAC testing.

Key Points: 
  • UltraViolet Devices, Inc. (UVDI) announced its V-MAX UV-C air disinfection technology has achieved 99.99% inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in a single-pass in moving airstream HVAC testing.
  • (Photo: Business Wire)
    In the independent testing, UVDI V-MAX UV-C air disinfection technology eliminated 99.99% of SARS-CoV-2 in a single pass at an airflow rate of 500 feet per minute.
  • To confirm effectiveness against airborne SARS-CoV-2 in a moving airstream, Innovative Bioanalysis used a HVAC duct test based on a modified ISO 15714 and ASHRAE 185.1 standard.
  • This novel testing underlines UVDIs UV-C technologys effectiveness against airborne SARS-CoV-2, stated Dr. Ashish Mathur, Ph.D., UVDI Vice President of Innovation and Technology.

AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th

Retrieved on: 
Thursday, March 11, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Stock market, Animal diseases, Coronavirus disease, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus, Microcap stock, Severe acute respiratory syndrome

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

Key Points: 
  • The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
  • The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.
  • To request complimentary investor registration: please visit the following website at www.investorsummitgroup.com
    therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

TurnSole Announces Regulatory Authority Approval and Subsequent Initiation of a Phase Ib/II Trial to evaluate the efficacy and the safety of TS-020 in acute COVID-19 viral infection in Patients with Severe Infection with Risk of Progression

Retrieved on: 
Thursday, March 4, 2021
Animal diseases, Medical specialties, Health, Aspergillosis, Severe acute respiratory syndrome, Antiviral drug, Coronavirus disease

"Preclinical studies demonstrated that TS-020 interferes with SARS-CoV2 replication, triggers antiviral mechanisms of the infected cells and promotes anti-inflammatory immune cell differentiation.

Key Points: 
  • "Preclinical studies demonstrated that TS-020 interferes with SARS-CoV2 replication, triggers antiviral mechanisms of the infected cells and promotes anti-inflammatory immune cell differentiation.
  • COVID-19 patients with acute respiratory distress syndrome due to viral infection are at risk of secondary complications like invasive aspergillosis.
  • TurnSole utilizes its breakthrough proprietary SEMY-TEC platform to develop personalized medicine for major unmet clinical needs within weeks of diagnosis.
  • The Companys asset portfolio contains compounds across a variety of indications and are protected by global composition of matter Intellectual Property.

EPA Approves Three Sani Professional Sanitizing and Disinfecting Products for Use Against SARS-CoV-2 virus

Retrieved on: 
Wednesday, March 3, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Animal diseases, Spray, Coronavirus disease, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

Sani Professional No-Rinse Sanitizing Wipes, Disinfecting Wipes, and No-Rinse Sanitizing spray are now on EPA List N.

Key Points: 
  • Sani Professional No-Rinse Sanitizing Wipes, Disinfecting Wipes, and No-Rinse Sanitizing spray are now on EPA List N.
    The expanded label claims against SARS-CoV-2, the virus that causes COVID-19, have met EPA efficacy requirements for hard, nonporous surfaces based on test results conducted by Microbac Laboratories.
  • Microbac conducted and released the following test results of the following products against the SARS-CoV-2 virus: No-Rinse Sanitizing Wipes and No-Rinse Sanitizing Spray are 99.9% effective against the virus in 1 minute.
  • Sani Professional is committed to provide our customers with products that improve food safety and public health," said Esperanza Carrion, Vice President and General Manager of Sani Professional.
  • No-Rinse Sanitizing wipes, Disinfectingwipes and No-Rinse Sanitizing spray are all included on the EPA's List N: Disinfectants for Coronavirus (COVID-19).